findmyKOL

David Dingli, MD

Basic profile

Mayo Clinic

ORCID↗NPI↗
✓ Full record
RegionRochester, MN · MidwestSpecialtyHematologyFocusHematology
Active KOLfindmyKOL type: RegionalLatest publication2020Online presenceNot yet checkedPayments2021 onwardNIH funding2011–2015

David Dingli is a Hematology physician affiliated with Mayo Clinic. OpenAlex indexes 1,100 publications with 31,438 citations (h-index 89). By OpenAlex citation count, this profile ranks in the top 10% of Hematology profiles in the findmyKOL directory.

Overview

Scholarship

indexed output and impact (OpenAlex)
View publications ↓
1,100publications

Distinct works indexed by OpenAlex, matched via ORCID.

31,438citations

Total citations across indexed works.

89h-index

Hirsch index, productivity × impact (OpenAlex).

Clinical & industry

trials, payments and federal funding
20companies · 2021 onward

Companies reporting payments to CMS. Facts, not judgments.

View payments ↓
1NIH grants · 2011–2015

Federally funded research awards.

View funding ↓

Contact

The practice address and phone this provider lists in the federal NPPES (CMS) registry.

Practice address

200 1st St SW
Rochester, MN 559050001

Telephone

507-284-2511

Provider last certified this registry record 13 Aug 2020.

View the NPPES registry record

Industry payments

20 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:

View the CMS Open Payments record ↗

Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.

Medicare prescribing footprint (2024)

The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.

  • Anti-infectives

    90.3%
    SARS-CoV-2 Nucleotide Analog RNA Polymerase Inhibitor65.8%
    Remdesivir100%
    Part B, office-administered≥19 patients
    Human Immunoglobulin G21.9%
    Immune globulin100%
    Part B, office-administered≥13 patients

    + 5 more classes in this area

  • Cancer & immunology

    3.1%
    Thalidomide Analog2.3%
    Revlimid71%Lenalidomide19%Pomalyst10%
    Part D<11 patients
    BCL-2 Inhibitor0.3%
    Venclexta100%
    Part D<11 patients

    + 2 more classes in this area

  • Dermatology

    2.2%
    Herpesvirus Nucleoside Analog DNA Polymerase Inhibitor2.2%
    Acyclovir100%
    Part D≥32 patients
Where care is delivered (Part B)1.2% facility · 98.8% office

Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.

NIH funding

1 NIH research award on record, funded 2011–2015 per NIH RePORTER. The latest:

Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.

Publications

Matched to this physician's OpenAlex author record; most-cited works shown first.

Similar KOLs

Other experts from the same institution or the same specialty.

A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments, shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”